These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27058929)

  • 1. Imprecision Medicine: A One-Size-Fits-Many Approach for Muscle Dystrophy.
    Breitbart A; Murry CE
    Cell Stem Cell; 2016 Apr; 18(4):423-4. PubMed ID: 27058929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
    Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
    Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy.
    Cai A; Kong X
    Hum Gene Ther Methods; 2019 Jun; 30(3):71-80. PubMed ID: 31062609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
    Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
    J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.
    Young CS; Hicks MR; Ermolova NV; Nakano H; Jan M; Younesi S; Karumbayaram S; Kumagai-Cresse C; Wang D; Zack JA; Kohn DB; Nakano A; Nelson SF; Miceli MC; Spencer MJ; Pyle AD
    Cell Stem Cell; 2016 Apr; 18(4):533-40. PubMed ID: 26877224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exon Snipping in Duchenne Muscular Dystrophy.
    Kemaladewi DU; Cohn RD
    Trends Mol Med; 2016 Mar; 22(3):187-189. PubMed ID: 26856237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duchenne muscular dystrophy: CRISPR/Cas9 treatment.
    Mendell JR; Rodino-Klapac LR
    Cell Res; 2016 May; 26(5):513-4. PubMed ID: 26926391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional correction of dystrophin actin binding domain mutations by genome editing.
    Kyrychenko V; Kyrychenko S; Tiburcy M; Shelton JM; Long C; Schneider JW; Zimmermann WH; Bassel-Duby R; Olson EN
    JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells.
    Maggio I; Liu J; Janssen JM; Chen X; Gonçalves MA
    Sci Rep; 2016 Nov; 6():37051. PubMed ID: 27845387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy.
    Amoasii L; Long C; Li H; Mireault AA; Shelton JM; Sanchez-Ortiz E; McAnally JR; Bhattacharyya S; Schmidt F; Grimm D; Hauschka SD; Bassel-Duby R; Olson EN
    Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cautious welcome for gene editing of Duchenne muscular dystrophy in animal model.
    Hawkes N
    BMJ; 2016 Jan; 351():h7033. PubMed ID: 26729900
    [No Abstract]   [Full Text] [Related]  

  • 12. The emerging role of viral vectors as vehicles for DMD gene editing.
    Maggio I; Chen X; Gonçalves MA
    Genome Med; 2016 May; 8(1):59. PubMed ID: 27215286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic engineering: In vivo genome editing - growing in strength.
    Koch L
    Nat Rev Genet; 2016 Mar; 17(3):124. PubMed ID: 26781811
    [No Abstract]   [Full Text] [Related]  

  • 14. Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single stranded oligodeoxynucleotides induces stable expression of dystrophin in a mouse model for Duchenne muscular dystrophy.
    Nik-Ahd F; Bertoni C
    Stem Cells; 2014 Jul; 32(7):1817-30. PubMed ID: 24753122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromuscular disease: CRISPR/Cas9 gene-editing platform corrects mutations associated with Duchenne muscular dystrophy.
    Wood H
    Nat Rev Neurol; 2015 Apr; 11(4):184. PubMed ID: 25752950
    [No Abstract]   [Full Text] [Related]  

  • 16. Gene Editing for Duchenne Muscular Dystrophy Using the CRISPR/Cas9 Technology: The Importance of Fine-tuning the Approach.
    Tremblay JP; Iyombe-Engembe JP; Duchêne B; Ouellet DL
    Mol Ther; 2016 Nov; 24(11):1888-1889. PubMed ID: 27916992
    [No Abstract]   [Full Text] [Related]  

  • 17. Scalpel or Straitjacket: CRISPR/Cas9 Approaches for Muscular Dystrophies.
    Himeda CL; Jones TI; Jones PL
    Trends Pharmacol Sci; 2016 Apr; 37(4):249-251. PubMed ID: 26917062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immortalized skin fibroblasts expressing conditional MyoD as a renewable and reliable source of converted human muscle cells to assess therapeutic strategies for muscular dystrophies: validation of an exon-skipping approach to restore dystrophin in Duchenne muscular dystrophy cells.
    Chaouch S; Mouly V; Goyenvalle A; Vulin A; Mamchaoui K; Negroni E; Di Santo J; Butler-Browne G; Torrente Y; Garcia L; Furling D
    Hum Gene Ther; 2009 Jul; 20(7):784-90. PubMed ID: 19358679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duchenne muscular dystrophy: an updated review of common available therapies.
    Salmaninejad A; Valilou SF; Bayat H; Ebadi N; Daraei A; Yousefi M; Nesaei A; Mojarrad M
    Int J Neurosci; 2018 Sep; 128(9):854-864. PubMed ID: 29351004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.